55,010 Shares in Glaukos Corporation $GKOS Purchased by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. purchased a new position in shares of Glaukos Corporation (NYSE:GKOS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 55,010 shares of the medical instruments supplier’s stock, valued at approximately $7,688,000.

Several other institutional investors also recently bought and sold shares of GKOS. AQR Capital Management LLC raised its stake in shares of Glaukos by 2.6% during the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after buying an additional 198 shares during the period. Jones Financial Companies Lllp increased its holdings in Glaukos by 1,405.9% in the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after acquiring an additional 2,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Glaukos by 41.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after acquiring an additional 67,668 shares in the last quarter. M&T Bank Corp acquired a new position in Glaukos during the second quarter worth $203,000. Finally, Gamco Investors INC. ET AL raised its position in Glaukos by 10.7% during the second quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock worth $826,000 after acquiring an additional 773 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Stock Down 1.1%

Shares of NYSE GKOS opened at $179.95 on Friday. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $191.62. The stock has a market cap of $10.61 billion, a PE ratio of -55.37 and a beta of 0.78. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The company has a 50-day moving average of $162.64 and a 200 day moving average of $133.95.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company had revenue of $185.61 million during the quarter, compared to the consensus estimate of $150.93 million. During the same quarter in the prior year, the firm earned ($0.24) EPS. Glaukos’s quarterly revenue was up 49.6% on a year-over-year basis. As a group, sell-side analysts predict that Glaukos Corporation will post -0.32 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Joseph E. Gilliam sold 60,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the sale, the chief operating officer owned 72,588 shares of the company’s stock, valued at approximately $13,046,967.12. This trade represents a 45.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Alex R. Thurman sold 20,000 shares of Glaukos stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer owned 43,906 shares in the company, valued at approximately $7,908,787.78. The trade was a 31.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 113,025 shares of company stock valued at $19,600,006 over the last ninety days. 5.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. UBS Group assumed coverage on shares of Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price target for the company. Citigroup raised their price target on shares of Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Truist Financial lifted their price objective on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, HC Wainwright boosted their price objective on Glaukos from $168.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and an average target price of $178.08.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.